The potential for misuse and abuse of medications in ADHD: A review

Postgraduate Medicine

Volumn 126, Issue 5, 2014, Pages 64-81

  Clemow, David B ^a   Walker, Daniel J ^a  

^a Lilly USA   (United States)

Author keywords

Abuse; ADHD; Dependence; Diversion; Malingering; Misuse

Indexed keywords

AMPHETAMINE; AMPHETAMINE PLUS DEXAMPHETAMINE; ATOMOXETINE; CLONIDINE; COCAINE; DESIPRAMINE; DEXAMPHETAMINE; DOPAMINE; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE; NORADRENALIN; PHENTERMINE; PRESCRIPTION DRUG; PSYCHOTROPIC AGENT; RECREATIONAL DRUG; TRIAZOLAM; ADRENERGIC RECEPTOR AFFECTING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CENTRAL STIMULANT AGENT;

ACADEMIC ACHIEVEMENT; ATTENTION DEFICIT DISORDER; COLLEGE STUDENT; COMORBIDITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MISUSE; DRUG SAFETY; DRUG USE; MALINGERING; NONHUMAN; PREFRONTAL CORTEX; PREGNANT WOMAN; PRESCRIPTION DRUG DIVERSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBSTANCE ABUSE; SYSTEMATIC REVIEW (TOPIC); UNITED STATES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DRUG ABUSE; EPIDEMIOLOGY; HUMAN; PREVALENCE; PRIMARY HEALTH CARE; STATISTICS AND NUMERICAL DATA; STUDENT; SUBSTANCE-RELATED DISORDERS;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC UPTAKE INHIBITORS; AMPHETAMINE-RELATED DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; METHYLPHENIDATE; PRESCRIPTION DRUG DIVERSION; PREVALENCE; PRIMARY HEALTH CARE; STUDENTS; SUBSTANCE-RELATED DISORDERS;

EID: 84921719451     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.09.2801     Document Type: Review

References (183)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing: 2013.
2. Center for Medicare and Medicaid Services. Drug Diversion in the Medicaid Program: State Strategies for Reducing Prescription Drug Diversion in Medicaid. Baltimore, MD: United States Department of Health and Human Services; 2012. http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/MedicaidIntegrityProgram/ downloads/drugdiversion.pdf. Accessed August 26, 2014.
3. Bloom B, Jones LI, Freeman G. (2013). Summary Health Statistics for U.S. Children: National Health Interview Survey, 2012. National Center for Health Statistics. Vital Health Stat 10(258); 2013.
4. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.
5. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402-409.
6. Lara C, Fayyad J, de Graaf R, et al. Childhood predictors of adult ADHD: results from the WHO World Mental Health (WMH) Survey Initiative. Biol Psychiatry. 2009;65(1):46-54.
7. Biederman J, Petty CR, Clarke A, Lomedico A, Faraone SV. Predictors of persistent ADHD: an 11-year follow-up study. J Psychiatr Res. 2011;45(2):150-155.
8. Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of ADHD persistence into adulthood: results from the National Comorbidity Survey Replication. Biol Psychiatry. 2005;57(11):1442-1451.
9. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the future: national survey results on drug use, 1975-2011: vol II, college students and adults ages 19-50. Ann Arbor: Institute for Social Research, The University of Michigan; 2012. http://www.monitoringthefuture. org/pubs/monographs/mtf-vol2_2011.pdf. Accessed August 26, 2014.
10. Fuermaier AB, Tucha L, Koerts J, Mueller AK, Lange KW, Tucha O. Measurement of stigmatization towards adults with attention deficit hyperactivity disorder. PLoS One. 2012;7(12):e51755.
11. Cascade E, Kalali AH. Weisler RH, Lenderts S. Seasonality and the changing adult/child prescription ratios in ADHD therapy. Psychiatry (Edgmont). 2008;5(1):23-25.
12. Suhr J, Hammers D, Dobbins-Buckland K, Zimak E, Hughes C. The relationship of malingering test failure to self-reported symptoms and neuropsychological findings in adults referred for ADHD evaluation. Arch Clin Neuropsychol. 2008;23(5):521-530.
13. Musso MW, Gouvier WD. "Why is this so hard?" A review of detection of malingered ADHD in college students. J Attention Discord. 2014;18(3):186-201.
14. Sullivan BK, May K, Galbally L. Symptom exaggeration by college adults in attention-deficit hyperactivity disorder and learning disorder assessments. Appl Neuropsychol. 2007;14(3):189-207.
15. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011;69(12):e145-e157.
16. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Application. 3rd ed. New York, NY: Cambridge University Press; 2008.
17. Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2012;51(4):356-367.
18. Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry. 2005;57(11):1377-1384.
19. Arnsten AFT. Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry. 2011;69(12):e89-e99.
20. Murnane KS, Howell LL. Neuroimaging and drug taking in primates. Psychopharmacology (Berl). 2011;216(2):153-171.
21. Whitelaw RB, Markou A, Robbins TW, Everitt BJ. Excitotoxic lesions of the basolateral amygdala impair the acquisition of cocaineseeking behaviour under a second-order schedule of reinforcement. Psychopharmacology (Berl). 1996;127(3):213-224.
22. Hutcheson DM, Everitt BJ. The effects of selective orbitofrontal cortex lesions on the acquisition and performance of cue-controlled cocaine seeking in rats. Ann N Y Acad Sci. 2003;1003:410-411.
23. Ito R, Robbins TW, Everitt BJ. Differential control over cocaine seeking behavior by nucleus accumbens core and shell. Nat Neurosci. 2004;7(4):389-397.
24. Ito R, Dalley JW, Howes SR, Robbins TW, Everitt BJ. Dissociation in conditioned dopamine release in the nucleus accumbens core and shell in response to cocaine cues and during cocaine-seeking behavior in rats. J Neurosci. 2000;20(19):7489-7495.
25. Rowlett JK, Platt DM, Yao WD, Spealman RD. Modulation of heroin and cocaine self-administration by dopamine D1-and D2-like receptor agonists in rhesus monkeys. J Pharmacol Exp Ther. 2007;321(3):1135-1143.
26. Economidou D, Dalley JW, Everitt BJ. Selective norepinephrine reuptake inhibition by atomoxetine prevents cue-induced heroin and cocaine seeking. Biol Psychiatry. 2011;69(3):266-274.
27. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in the prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699-711.
28. Gamo NJ, Wang M, Arnsten AFT. Methylphenidate and atomoxetine enhance prefrontal function through e2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry. 2010;49(10):1011-1023.
29. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 2002;67(2):149-156.
30. Kawaura K, Karasawa J, Chaki S, Hikichi H. Stimulation of postsynapse adrenergic a2a receptor improves attention/cognition performance in an animal model of attention deficit hyperactivity disorder. Behav Brain Res. 2014;270:349-356.
31. Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend. 2008;95(1-2):140-146.
32. Upadhyaya HP, Kroutil LA, Deas D, Durell TM, Van Brunt DL, Novak SP. Stimulant formulation and motivation for nonmedical use of prescription attention-deficit/hyperactivity disorder medications in a college-aged population. Am J Addict. 2010;19(6):569-577.
33. McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse. 2004;39(7):1095-1116.
34. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45(4):408-414.
35. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry. 2005;57(11):1215-1220.
36. Upadhyaya HP. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder. J Clin Psychiatry. 2007;68(Suppl 11):23-30.
37. Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis. 1997;185(8):475-482.
38. Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. CMAJ. 2001;165(8):1039-1044.
39. Poulin C. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots. Addiction. 2007;102(5):740-751.
40. Upadhyaya HP, Rose K, Wang W, et al. Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J Child Adolesc Psychopharmacol. 2005;15(5):799-809.
41. Biederman J, Faraone SV, Mick E, et al. High risk for attention deficit hyperactivity disorder among children of parents with childhood onset of the disorder: a pilot study. Am J Psychiatry. 1995;152(3):431-435.
42. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1997;36(1):21-29.
43. Molina BSG, Pelham WE Jr. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol. 2003;112(3):497-507.
44. Weiss M, Murray C. Assessment and management of attention-deficit hyperactivity disorder in adults. CMAJ. 2003;168(6):715-722.
45. Aldridge AP, Kroutil LA, Cowell AJ, Reeves DB, Van Brunt DL. Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder. Pharmacoeconomics. 2011;29(7):621-635.
46. Bredeloux P, Dubuc I, Costentin J. Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission. Br J Pharmacol. 2007;150(6):711-719.
47. Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem. 2010;114(1):259-270.
48. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem. 1997;68(5):2032-2037.
49. Stahl SM. Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry. 2003;64(2):110-111.
50. Volkow ND, Wang GJ, Fischman MW, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 1997;386(6627):827-830.
51. Kahlig KM, Binda F, Khoshbouei H, et al. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A. 2005;102(9):3495-3500.
52. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry. 2003;160(11):1909-1918.
53. Wetzell BB, Muller MM, Cobuzzi JL, Hurwitz ZE, DeCicco-Skinner K, Riley AL. Effect of age on methylphenidate-induced conditioned taste avoidance and related BDNF/TrkB signaling in the insular cortex of the rat. Psychopharmacology (Berl). 2014;231(8):1493-1501.
54. Andersen SL, Arvanitogiannis A, Pliakas AM, LeBlanc C, Carlezon WA Jr. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat Neurosci. 2002;5(1):13-14.
55. Carlezon WA Jr, Mague SD, Andersen SL. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry. 2003;54(12):1330-1337.
56. Brandon CL, Marinelli M, White FJ. Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons. Biol Psychiatry. 2003;54(12):1338-1344.
57. Schenk S, Izenwasser S. Pretreatment with methylphenidate sensitizes rats to the reinforcing effects of cocaine. Pharmacol Biochem Behav. 2002;72(3):651-657.
58. Schramm-Sapyta NL, Cha YM, Chaudhry S, Wilson WA, Swartzwelder HS, Kuhn CM. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology (Berl). 2007;191(4):867-877.
59. Doremus-Fitzwater TL, Varlinskaya EI, Spear LP. Motivational systems in adolescence: possible implications for age differences in substance abuse and other risk-taking behaviors. Brain Cogn. 2010;72(1):114-123.
60. Bogle KE, Smith BH. Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr Drug Abuse Rev. 2009;2(2):157-176.
61. Dupont RL, Coleman JJ, Bucher RH, Wilford BB. Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Am J Addict. 2008;17(3):167-171.
62. Barrett SP, Darredeau C, Bordy LE, Pihl RO. Characteristics of methylphenidate misuse in a university student sample. Can J Psychiatry. 2005;50(8):457-461.
63. Teter CJ, McCabe SE, Boyd CJ, Guthrie SK. Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacotherapy. 2003;23(5):609-617.
64. Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy. 2006;26(10):1501-1510.
65. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE, Miech RA. Monitoring the future: national survey results on drug use, 1975-2013: volume I, secondary school students. Ann Arbor: Institute for Social Research, The University of Michigan; 2014. http:// www.monitoringthefuture.org/pubs/monographs/mtf-vol1_2012.pdf. Accessed August 26, 2014.
66. Darredeau C, Barrett SP, Jardin B, Pihl RO. Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. Hum Psychopharmacol. 2007;22(8):529-536.
67. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21-31.
68. Arias AJ, Gelernter J, Chan G, et al. Correlates of co-occurring ADHD in drug-dependent subjects: prevalence and features of substance dependence and psychiatric disorders. Addict Behav. 2008;33(9):1199-1207.
69. Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011;31(3):328-341.
70. Wilens TE, Martelon M, Joshi G, et al. Does ADHD predict substance use disorders? A 10-year follow-up study of young adults with ADHD. J Am Acad Child Adolesc Psychiatry. 2011;50(6):543-553.
71. Wilens TE, Morrison NR. Substance-use disorders in adolescents and adults with ADHD: focus on treatment. Neuropsychiatry (London). 2012;2(4):301-312.
72. Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psychiatry. 2003;64(Suppl 11):14-18.
73. Kollins SH. Abuse liability of medications used to treat attentiondeficit/ hyperactivity disorder (ADHD). Am J Addict. 2007;16(Suppl 1): 35-42; quiz 43-44.
74. Biederman J, Wilens T, Mick E, Spencer T, Faraone S. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics. 1999;104(2):e20.
75. Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol. 2005;15(5):764-776.
76. Wilens TE, Adamson J, Monuteaux MC, et al. Impact of prior stimulant treatment for attention-deficit hyperactivity disorder in the subsequent risk for cigarette smoking, alcohol, and drug use disorders in adolescent girls. Arch Pediatr Adolesc Med. 2008;162(10):916-921.
77. Mannuzza S, Klein RG, Truong NL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry. 2008;165(5):604-609.
78. Kollins SH, English J, Robinson R, Hallyburton M, Chrisman AK. Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). Psychopharmacology. 2009;204(1):73-83.
79. Merkel RL Jr, Kuchibhatla A. Safety of stimulant treatment in attention deficit hyperactivity disorder: part 1. Expert Opin Drug Saf. 2009;8(6):655-668.
80. Parasrampuria DA, Schoedel KA, Schuller R, et al. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol. 2007;27(5):459-467.
81. Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short-and long-acting oral methylphenidate. Am J Psychiatry. 2006;163(3):387-395.
82. Berman SM, Kuczenski R, McCracken JT, London ED. Potential adverse effects of amphetamine treatment on brain and behavior: a review [published correction appears in Mol Psychiatry. 2010;15(11):1121]. Mol Psychiatry. 2009;14(2):123-142.
83. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23(4):419-427.
84. Ermer JC, Dennis K, Haffey MB, et al. Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. Clin Drug Investig. 2011;31(6):357-370.
85. Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009;23(4):410-418.
86. Cortese S, Holtmann M, Banaschewski T, et al; European ADHD Guidelines Group. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54(3):227-246.
87. Intuniv [package insert]. Wayne, PA: Shire Inc; 2011.
88. Kapvay [package insert]. Florham Park, NJ: Shionogi Pharma Inc; 2010.
89. Ma CL, Qi XL, Peng JY, Li BM. Selective deficit in no-go performance induced by blockade of prefrontal cortical alpha 2-adrenoceptors in monkeys. Neuroreport. 2003;14(7):1013-1016.
90. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001;21(2):223-228.
91. Fox HC, Seo D, Tuit K, et al. Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: preliminary findings. J Psychopharmacol. 2012;26(7):958-972.
92. Fox HC, Morgan PT, Sinha R. Sex differences in guanfacine effects on drug craving and stress arousal in cocaine-dependent individuals. Neuropsychopharmacology. 2014;39(6):1527-1537.
93. Kim S, Bobeica I, Gamo NJ, Arnsten AF, Lee D. Effects of 9-2A adrenergic receptor agonist on time and risk preference in primates. Psychopharmacology (Berl). 2012;219(2):363-375.
94. Sofuoglu M, DeVito EE, Waters AJ, Carroll KM. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology. 2013;64:452-463.
95. Gowing L, Farrell MF, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2014;3:CD002024.
96. Dennison SJ. Clonidine abuse among opiate addicts. Psychiatr Q. 2001;72(2):191-195.
97. Conway T, Balson A. Concomitant abuse of clonidine and heroin. South Med J. 1993;86(8):954-956.
98. Dy EC, Yates WR. Atypical drug abuse: a case report involving clonidine. Am Fam Physician. 1996;54(3):1035-1038.
99. Schaut J, Schnoll SH. Four cases of clonidine abuse. Am J Psychiatry. 1983;140(12):1625-1627.
100. Anderson F, Paluzzi P, Lee J, Huggins G, Svikis D. Illicit use of clonidine in opiate-abusing pregnant women. Obstet Gynecol. 1997;90(5):790-794.
101. Schindler EAD, Tirado-Morales DJ, Kushon D. Clonidine abuse in a methadone-maintained, clonazepam-abusing patient. J Addict Med. 2013;7(3):218-219.
102. Bender TS, Abdel-Rahman AA. Differential central NOS-NO signaling underlies clonidine exacerbation of ethanol-evoked behavioral impairment. Alcohol Clin Exp Res. 2010;34(3):555-566.
103. Yoon MH, Choi JI. Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test. Anesthesiology. 2003;99(3):701-707.
104. Sharma A, Newton W. Clonidine as a drug of abuse. J Am Board Fam Pract. 1995;8(2):136-138.
105. Gahr M, Freudenmann RW, Eller J, Schönfeldt-Lecuona C. Abuse liability of centrally acting non-opioid analgesics and muscle relaxants-a brief update based on a comparison of pharmacovigilance data and evidence from the literature. Int J Neuropsychopharmacol. 2014;17(6):957-959.
106. Stahl SM. Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex. J Clin Psychiatry. 2003;64(3):230-231.
107. Stahl SM. Neurotransmission of cognition, part 1, dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine. J Clin Psychiatry. 2003;64(1):4-5.
108. Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004;64(2):205-222.
109. Upadhyaya HP, Desaiah D, Schuh KJ, et al. A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 2013;226(2):189-200.
110. Lile JA, Stoops WW, Durell TM, Glaser PEA, Rush CR. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. Exp Clin Psychopharmacol. 2006;14(2):136-147.
111. Fitzgerald PJ. Elevated norepinephrine may be a unifying etiological factor in the abuse of a broad range of substances: alcohol, nicotine, marijuana, heroin, cocaine, and caffeine. Substance Abuse. 2013;7:171-183.
112. Lategan AJ, Marien MR, Colpaert FC. Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res. 1990;523(1):134-138.
113. Economidou D, Pelloux Y, Robbins TW, Dalley JW, Everitt BJ. High impulsivity predicts relapse to cocaine-seeking after punishmentinduced abstinence. Biol Psychiatry. 2009;65(10):851-856.
114. Gasior M, Bergman J, Kallman MJ, Paronis CA. Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys. Neuropsychopharmacology. 2005;30(4):758-764.
115. Wee S, Woolverton WL. Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. Drug Alcohol Depend. 2004;75(3):271-276.
116. Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther. 2010;88(1):69-78.
117. Wernicke JF, Adler L, Spencer T, et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol. 2004;24(1):30-35.
118. Substance Abuse and Mental Health Services Administration. Treatment for Stimulant Use Disorders. Center for Substance Abuse Treatment, US Department of Health and Human Services: Rockville, MD; 1999.
119. Carlson GA, Kelly KL. Stimulant rebound: how common is it and what does it mean? J Child Adolesc Psychopharmacol. 2003;13(2):137-142.
120. Strattera [package insert]. Indianpolis, IN: Eli Lilly and Company; 2014.
121. McCabe SE, Teter CJ, Boyd CJ, Guthrie SK. Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12th grade students in the United States, 2001. J Adolescent Health. 2004;35(6):501-504.
122. McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey [published corrections appears in Addiction. 2005;100(4):573]. Addiction. 2005;100(1):96-106.
123. McCabe SE, Boyd CJ, Teter CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health. 2006;54(5):269-278.
124. McCabe SE, Teter CJ, Boyd CJ. Medicaluse, illicit use and diversion of prescription stimulant medication. J Psychoactive Drugs. 2006;38(1):43-56.
125. Teter CJ, McCabe SE, Cranford JA, Boyd CJ, Guthrie SK. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health. 2005;53(6):253-262.
126. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the future national survey results on drug use, 1975-2012: volume 2, college students and adults ages 19-50. Ann Arbor: Institute for Social Research, The University of Michigan; 2014.
127. Rabiner DL. Stimulant prescription cautions: addressing misuse, diversion, and malingering. Curr Psychiatry Rep. 2013;15(7):375.
128. Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med. 2008;10(5):111.
129. Harstad E, Levy S; Committee on Substance Abuse. Attentiondeficit/ hyperactivity disorder and substance abuse. Pediatrics. 2014;134(1):e293-e301.
130. Mao AR, Babcock T, Brams M. ADHD in adults: current treatment trends with consideration of abuse potential of medications. J Psychiatr Pract. 2011;17(4):241-250.
131. Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzwelder HS. The misuse and diversion of prescribed ADHD medications by college students. J Atten Disord. 2009;13(2): 144-153.
132. Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzwelder HS. Motives and perceived consequences of nonmedical ADHD medication use by college students: are students treating themselves for attention problems? J Attent Disord. 2009;13(3): 259-270.
133. Sclar DA, Robison LM, Castillo LV, Bowen KA, Schmidt JM, Oganov AM. Attention deficit/hyperactivity disorder among adults in the United States: trend in diagnosis and use of pharmacotherapy. Pharmaceut Med. 2012;26(2):97-101.
134. Zuvekas SH, Vitiello B. Stimulant medication use among U.S. children: a 12-year perspective. Am J Psychiatry. 2012;169(2):160-166.
135. Jasinski LJ, Harp JP, Berry DTR, Shandera-Ochsner AL, Mason LH, Ranseen JD. Using symptom validity tests to detect malingered ADHD in college students. Clin Neuropsychol. 2011;25(8):1415-1428.
136. Novak SP, Kroutil LA, Williams RL, Van Brunt DL. The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy. 2007;2:32.
137. Sansone RA, Sansone LA. Faking attention deficit hyperactivity disorder. Innov Clin Neurosci. 2011;8(8):10-13.
138. Quinn CA. Detection of malingering in assessment of adult ADHD. Arch Clin Neuropsychol. 2003;18(4):379-395.
139. Harrison AG, Edwards MJ, Parker KCH. Identifying students faking ADHD: preliminary findings and strategies for detection. Arch Clin Neuropsychol. 2007;22(5):577-588.
140. Jachimowicz G, Geiselman RE. Comparison of ease of falsification of attention deficit hyperactivity disorder diagnosis using standard behavioral rating scales. Cognitive Science Online. 2004;2:6-20. http://cogsci-online.ucsd.edu/. Accessed August 26, 2014.
141. Lee Booksh R, Pella RD, Singh AN, Drew Gouvier W. Ability of college students to simulate ADHD on objective measures of attention. J Atten Disord. 2010;13(4):325-338.
142. Tucha L, Sontag TA, Walitza S, Lange KW. Detection of malingered attention deficit hyperactivity disorder. Atten Defic Hyperact Disord. 2009;1(1):47-53.
143. Sollman MJ, Ranseen JD, Berry DTR. Detection of feigned ADHD in college students. Psychol Assess. 2010;22(2):325-335.
144. Harp JP, Jasinski LJ, Shandera-Ochsner AL, Mason LH, Berry DTR. Detection of malingered ADHD using the MMPI-2-RF. Psychol Inj Law. 2011;4(1):32-43.
145. Young CJ, Gross AM. Detection of response bias and noncredible performance in adult attention-deficit/hyperactivity disorder. Arch Clin Neuropsychol. 2011;26(3):165-175.
146. Marshall P, Schroeder R, O'Brien J, et al. Effectiveness of symptom validity measures in identifying cognitive and behavioral symptom exaggeration in adult attention deficit hyperactivity disorder. Clin Neuropsychol. 2010;24(7):1204-1237.
147. Suhr JA, Sullivan BK, Rodriguez JL. The relationship of noncredible performance to continuous performance test scores in adults referred for attention-deficit/hyperactivity disorder evaluation. Arch Clin Neuropsychol. 2011;26(1):1-7.
148. Substance Abuse and Mental Health Services Administration. Results from the 2005 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, US Department of Health and Human Services; Rockville, MD; 2006.
149. Sepúlveda DR, Thomas LM, McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Misuse of prescribed stimulant medication for ADHD and associated patterns of substance use: preliminary analysis among college students. J Pharm Pract. 2011;24(6):551-560.
150. Cohen AL, Jhung MA, Budnitz DS. Stimulant medications and attention deficit-hyperactivity disorder. N Engl J Med. 2006;354(21):2294-2295.
151. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN Report: Emergency Department Visits Involving Attention Deficit/Hyperactivity Disorder Stimulant Medications. Rockville, MD. http://www.samhsa. gov/data/2k13/dawn073/sr073-add-adhd-medications.htm. Accessed August 26, 2014.
152. Klein-Schwartz W, McGrath J. Poison centers' experience with methylphenidate abuse in pre-teens and adolescents. J Am Acad Child Adolesc Psychiatry. 2003;42(3):288-294.
153. Merkel RL. Safety of stimulant treatment in attention deficit hyperactivity disorder: part II. Expert Opin Drug Saf. 2010;9(6):917-935.
154. Vetter VL, Elia J, Erickson C, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing [published correction appears in Circulation. 2009;120(7):e55-e59]. Circulation. 2008;117(18):2407-2423.
155. Kaye S, McKetin R, Duflou J, Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction. 2007;102(8):1204-1211.
156. Cox S, Posner SF, Kourtis AP, Jamieson DJ. Hospitalizations with amphetamine abuse among pregnant women. Obstet Gynecol. 2008;111(2 Pt 1):341-347.
157. Advokat C. Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD. J Atten Disord. 2007;11(1):8-16.
158. Bamford NS, Zhang H, Joyce JA, et al. Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration. Neuron. 2008;58(1):89-103.
159. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the future national survey results on drug use, 1975-2010. Volume II: college students and adults ages 19-50. Ann Arbor: Institute for Social Research, The University of Michigan; 2011.
160. Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood-a naturalistic long-term follow-up study. Addict Behav. 2014;39(1):325-328.
161. Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/ hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry. 2011;50(1):9-21.
162. Barkley RA, Fischer M, Smallish L, Fletcher K. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics. 2003;111(1):97-109.
163. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/ hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111(1):179-185.
164. Wilson JJ, Levin FR. Attention-deficit/hyperactivity disorder and early-onset substance use disorders. J Child Adolesc Psychopharmacol. 2005;15(5):751-763.
165. Sweeney CT, Sembower MA, Ertischek MD, Shiffman S, Schnoll SH. Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse. J Addict Dis. 2013;32(1):1-10.
166. Biederman J, Monuteaux MC, Spencer T, Wilens TE, MacPherson HA, Faraone SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry. 2008;165(5):597-603.
167. Volkow ND, Wang GJ, Newcorn J, et al. Brain dopamine transporter levels in treatment and drug naïve adults with ADHD. Neuroimage. 2007;34(3):1182-1190.
168. Volkow ND, Wang GJ, Newcorn J, et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007;64(8):932-940.
169. Volkow ND, Wang GJ, Kollins SH, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009;302(10):1084-1091.
170. Chen LY, Strain EC, Alexandre PK, Alexander GC, Mojtabai R, Martins SS. Correlates of nonmedical use of stimulants and methamphetamine use in a national sample. Addict Behav. 2014;39(5):829-836.
171. Somkuwar SS, Jordan CJ, Kantak KM, Dwoskin LP. Adolescent atomoxetine treatment in a rodent model of ADHD: effects on cocaine self-administration and dopamine transporters in frontostriatal regions. Neuropsychopharmacology. 2013;38(13):2588-2597.
172. Jordan CJ, Harvey RC, Baskin BB, Dwoskin LP, Kantak KM. Cocaineseeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments. Drug Alcohol Depend. 2014;140:25-32.
173. Garnock-Jones KP, Keating GM. Spotlight on atomoxetine in attentiondeficit hyperactivity disorder in children and adolescents. CNS Drugs. 2010;24(1):85-88.
174. McCabe SE, West BT. Medical and nonmedical use of prescription stimulants: results from a national multicohort study. J Am Acad Child Adolesc Psychiatry. 2013;52(12):1272-1280.
175. Kroutil LA, Van Brunt DL, Herman-Stahl MA, Heller DC, Bray RM, Penne MA. Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend. 2006;84(2):135-143.
176. Cruz MP. Guanfacine extended-release tablets (Intuniv), a nonstimulant selective alpha(2 A)-adrenergic receptor agonist for attentiondeficit/ hyperactivity disorder. P T. 2010;35(8):448-451.
177. Erder MH, Xie J, Signorovitch JE, et al. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matchingadjusted indirect comparison. Appl Health Econ Health Policy. 2012;10(6):381-395.
178. Adderall XR [package insert]. Wayne, PA: Shire Inc; 2013.
179. Vyvanse [package insert]. Wayne, PA: Shire Inc; 2012.
180. Concerta [package insert]. Titusville, NJ: McNeil Pediatrics; 2010.
181. Focalin XR [package insert]. Gainesville, GA: Novartis; 2012.
182. Lensing MB, Zainer P, Sandvik L, Opjordsmoen S. Adults with ADHD: use and misuse of stimulant medication as reported by patients and their primary care physicians. Atten Defic Hyperact Disord. 2013;5(4):369-376.
183. Kratochvil CJ, Heiligenstein JH, Dittman R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41(7):776-784.